Background: Oral anticoagulants, including direct oral anticoagulants (DOACs), are
| INTRODUCTION
Catheter ablation (CA) is an established treatment for patients with drug-refractory atrial fibrillation (AF). [1] [2] [3] Several studies have reported that CA for AF reduced the risk of thromboembolism (TE), including stroke. Anticoagulation therapy discontinuation could be considered in some AF patients who undergo CA. 4 However, AF patients with a high risk of TE or a history of stroke should continue using anticoagulant drugs, even if they have undergone CA for AF. 4, 5 Recently, the use of direct oral anticoagulants (DOACs) is increasing as a substitute for warfarin in patients with AF, 6 and several large clinical studies have evaluated the safety and efficacy of DOACs around CA for AF. [7] [8] [9] [10] [11] However, the data are limited regarding adverse events with the long-term use of DOACs in patients requiring continuous anticoagulant drugs after CA for AF.
The purpose of this study was to compare the midterm incidence of TE and bleeding complications after CA among AF patients receiving postprocedural treatment with warfarin or DOACs.
| ME TH ODS

| Subjects
We identified consecutive patients who underwent radiofrequency CA between January 2013 and July 2015 at the Japanese Red Cross Musashino Hospital. All patients were required to have at least one filled prescription for an oral anticoagulant (OAC).
Patients who continued taking an OAC for at least 4 weeks prior to CA and at least 4 weeks afterward were included in this study, because we aimed to examine the relationship between adverse events and the OAC status in patients with AF after CA. Neither the type of AF (paroxysmal, persistent, or permanent) nor the number of AF ablation sessions (1st, 2nd, 3rd, or 4th) was considered when we selected patients. We obtained clinical data including the drug dosage and results of laboratory examinations from the patients' medical records. A total of 731 AF patients were identified as consecutive patients who underwent CA in this study. We excluded 102 AF patients with the following conditions from this study: those with 2 or more OACs, those with an overdose of DOACs, those in whom CA was performed without of the use of an OAC, those in whom CA was performed less than 4 weeks after DOAC was started, those in whom an OAC was changed immediately after CA, and those in whom follow-up data for more than 4 weeks after CA was unavailable. Therefore, 629 AF patients were included in the current analysis. This study was approved by the institutional review board of the Japanese Red Cross Musashino Hospital, and this study complied with the ethical principles of the Declaration of Helsinki and the Japanese Ethical Guideline for
Medical and Health Research Involving Human Subjects. All participants were notified that they would be included in the study, and we explained to them that they were free to opt out of participation at any time. 
| Baseline characteristics and OAC status
| Follow-up strategy
Follow-up data were obtained at routine or additional visits at our institution. The patients were followed from 4 weeks after CA until the end of the follow-up period (September 2016) or until the OAC was discontinued, the OAC was changed, or the next CA session was performed for recurrent AF. The OAC was discontinued at 3 to 6 months after CA in AF recurrence-free patients without the risk factors of TE. TE and bleeding complications were evaluated in patients in the warfarin and DOACs groups during the follow-up period.
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| Efficacy and safety endpoints
The efficacy endpoint was evaluated in terms of the incidence of TE complications, including TIA and symptomatic cerebral infarction.
Patients with silent cerebral infarction as seen on magnetic resonance imaging were not included in this study. The safety endpoint was evaluated in terms of major and minor bleeding complications.
The major bleeding complications were defined as fatal bleeding, symptomatic bleeding at a critical site, bleeding causing a decrease in the hemoglobin level of ≥2 g/dL, or bleeding requiring transfusion. 15 Minor bleeding complications were defined as bleeding that did not require invasive treatment, and these complications included epistaxis, hematuria, bloody stool, bloody sputum, hematoma, subcutaneous hemorrhage, subconjunctival hemorrhage, intraoral hemorrhage, and pericardial effusion. All analyses were performed with JMP software version 12.2.0 (SAS Institute Inc., Cary, NC, USA). A two-sided P-value <.05 was considered statistically significant.
| RESULTS
| Patient characteristics
We included 629 consecutive AF patients in the analyses. There were no cases in which OAC was discontinued within 4 weeks after CA due to bleeding complications in this study. The patients'
clinical characteristics are shown in higher ratio of patients with paroxysmal AF in the warfarin group than in the DOACs group. The incidence of heart failure, as well as the brain natriuretic peptide level, was higher in the warfarin group than in the DOACs group. The CHA2DS2-VASc score and HAS-BLED score were similar between the 2 groups; however, creatinine clearance was lower in the warfarin group than in the DOACs group. Table 3 shows the clinical outcomes. In the warfarin group, no TE complications occurred during the follow-up period, whereas all types of bleeding complications occurred in 32 patients (11.0%).
| OAC management
| Clinical endpoints
Major bleeding complications occurred in 6 patients (2.1%), and minor bleeding complications occurred in 26 (8.9%). In the DOACs group, no TE complications occurred during the follow-up period, whereas all types of bleeding complications occurred in 15 patients (4.5%). Major bleeding complications occurred in 4 patients (1.2%) and minor bleeding complications occurred in 12 (3.6%). When the rates of TE complications were compared between the warfarin and DOAC groups, no significant differences were found. However, patients in the warfarin group had a significantly higher rate of minor bleeding complications than did those in the DOACs group (8.9% vs 3.6%, respectively, P = .005). All types of bleeding complications occurred more frequently in the warfarin group than in the DOACs group (11.0% vs 4.5%, respectively, P = .002). Kaplan-Meier analysis showed that the rate of all types of bleeding complications was significantly higher in the warfarin group than in the DOACs group during a median follow-up period of 7 months (range: 4-14 months) after CA (log-rank; P = .024). In addition, when we analyzed the clinical outcomes of 591 AF patients, excluding those with off-label under dose or non-suggested-dose DOACs, we obtained same results.
| DISCUSSION
The main findings of the present study were as follows: (i) there was no significant difference in the CHA2DS2-VASc score and HAS-BLED score (including the rate of combined antiplatelet drugs) between the warfarin and DOACs groups; (ii) there was no significant difference in the prevalence of TE and major bleeding complications between the warfarin and DOACs groups during the follow-up period; (iii) patients in the warfarin group had more minor bleeding complications than did those in the DOACs group, and the rate of all types of bleeding complications was significantly higher in the warfarin group than that in the DOACs group, as assessed with the Kaplan-Meier analysis; and (iv) in a multivariate Cox proportional analysis for all bleeding complications, the use of DOACs was significantly associated with a decreased risk of all types of bleeding complications.
Randomized controlled trials, such as the RE-LY, ROCKET AF, and ARISTOTLE, have reported the efficacy and safety of DOACs compared with warfarin. 6, [18] [19] [20] A previous meta-analysis reported that DOACs significantly reduced TE, including stroke, compared with warfarin, and were similar to warfarin regarding the occurrence of major bleeding complications. 21 Conversely, DOACs were reported to be associated with an increased risk of gastrointestinal bleeding compared with warfarin. 22 As real-world data, the Fushimi AF Registry study showed that there was no significant difference in the incidence of stroke, TE, and major bleeding complications between warfarin and DOACs. 23 However, the occurrence of minor bleeding complications was not reported in that study.
The present study showed that there was no significant difference in the midterm incidence of TE and major bleeding complications between the warfarin and DOACs groups, similar to the result of the Fushimi AF Registry study. Furthermore, the prevalence of major bleeding complications was similar to that in previous studies targeting AF patients who did not undergo CA. Meanwhile, the prevalence of TE complications was lower in our study than that which has been reported in previous studies. 6, [18] [19] [20] 23 We targeted patients undergoing CA for AF, which is why these patients experienced some reduction of TE complications compared with previous studies. 24 We showed that patients in the warfarin group had significantly more minor bleeding complications than did those in the Values are shown as the mean AE standard deviation or median (interquartile range) or n (%). DOACs, direct oral anticoagulants; BMI, body mass index; AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age ≧75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years and sex category; HAS-BLED, hypertension, abnormal renal function/liver function, stroke, prior bleeding, elderly (age ≧65 years), use of antiplatelet drugs/alcohol dependence, Labile international normalized ratio; CCr, creatinine clearance; OAC, oral anticoagulant.
reported that nonmajor bleeding, including minor bleeding, was less frequent in patients who were treated with apixaban than in those who were treated with warfarin; moreover, minor bleeding is very important, as it is a frequent clinical complication and often results in adverse outcomes including mortality and major bleeding events. 16 Although we were not able to prove whether the occurrence of minor bleeding was related to adverse outcomes because of the small number of patients who were included, considering this previous report, we consider that the present results are important.
In the present study, the HAS-BLED scores were similar between the 2 groups; however, creatinine clearance was lower in the warfarin group than in the DOACs group. Although creatinine clearance is generally an important factor of bleeding complications, the average value of creatinine clearance was more than 60 mL/min in the 2 groups. Thus, we speculated that the targeted patients in the present study were not at a high risk of bleeding complications in terms of renal function.
In the present study, there were some off-label under dose or non-suggested-dose DOAC users. The Fushimi AF Registry study mentioned that the use of off-label under dose DOAC might have influenced the clinical outcome. 23 However, in our study, only 11% of all DOAC users were prescribed off-label under dose or nonsuggested-dose DOACs; moreover, the same result was obtained Values are shown as the mean AE standard deviation or n (%). DOACs, direct oral anticoagulants; PT-INR, prothorombin time-international normalized ratio. In addition, in the present study, most of the unde dose DOAC users were in the dabigatran group. A reduced dose of dabigatran was proven to be noninferior to warfarin in previous studies. 30 Therefore, the use of an off-label under dose or non-suggested-dose DOAC may have had little influence on the clinical outcomes of the present study.
| Study limitations
The present study has several limitations. First, this study was a small-scale, retrospective, and observational study at a single institution. Therefore, the Cox proportional hazards modeling might have been biased, and special care should be taken when interpreting the present results. The adjusted HR of the HAS-BLED score was 1.222 (95% CI: 0.91-1.628, P = .179), which indicates that the HAS-BLED score showed a 22% increase in bleeding events as a 1-point increase; however, it was not statistically significant, likely due to several reasons. First, the sample size was small and all bleeding events occurred in only 47 patients in the present study. Thus, we may have lacked statistical power. Second, the mean HAS-BLED score of the AF patient group in the present study was 1.3, which was lower than that which has been reported in other studies. A low HAS-BLED score of the participants may result in a low incidence of bleeding events in this study. Second, data on the therapeutic time range in the warfarin group during the follow-up period was not available. Thus, the influences of the quality of warfarin control on clinical events are unknown. Third, adherence to an OAC regimen during the follow-up period is important; however, we did not investigate this factor. Finally, the rate of AF recurrence after CA was not investigated; therefore, the impact of AF recurrence on the clinical outcome, especially TE complications, is not known.
| CONCLUSIONS
This retrospective study is one of the first studies to evaluate the midterm follow-up of patients with TE and bleeding events after CA.
Furthermore, we found that the risk of TE complications in AF patients undergoing CA was similar among warfarin and DOACs users, whereas the risk of bleeding complications was lower in DOAC users than in warfarin users. DOACs might be suitable for patients requiring continuous OAC administration after CA for AF.
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